Oxford BioMedica is a world leading gene and cell therapy company focused on developing life changing treatments for serious diseases. They have built a platform of cutting-edge technologies and capabilities based on a lentivirus-base vectors called LentiVector®, with which they design, develop and produce gene and cell-based medicines for themselves and for their partners.
Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. It may be in vivo or ex vivo, the latter encompassing the field of cell therapy, whereby genetically modified cells are reintroduced to the body. Through their LentiVector® delivery platform, Oxford BioMedica has created a valuable and focused portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. They have a broader interest in multiple partnered royalty-bearing product candidates with Novartis, Sanofi and Immune Design, among others.